Galderma, the pure-play dermatology category leader, will be showcasing its innovative, science-based portfolio that spans the full spectrum of the fast-growing dermatology market at the 33rd European Academy of Dermatology and Venereology (EADV) congress taking place in Amsterdam, September 25-28, 2024.
Details on scientific presentations supported by Galderma at EADV 2024 can be found below.
|
Therapy area |
First author |
Abstract title and number |
Presentation time and location |
|
Nemolizumab* |
|||
|
Prurigo nodularis |
FJ. Legat |
Abstract #7987 Durability of response to nemolizumab in patients with moderate-to-severe prurigo nodularis: Results from a randomised placebo-controlled withdrawal Phase 3b study |
Late-breaking presentation Wednesday 25 September 2:15 – 2:30 pm CET Auditorium |
|
Atopic dermatitis |
D. Thaçi |
Abstract #7885 Nemolizumab long-term safety and efficacy up to 56 weeks in ARCADIA open-label extension study in adolescents and adults with moderate-to-severe atopic dermatitis |
Late-breaking presentation
Wednesday 25 September 3 – 3:15 pm CET Auditorium |
|
Atopic dermatitis |
E. Guttman-Yassky |
Abstract #8052 Tape-strips transcriptomic analysis from patients with moderate to severe atopic dermatitis treated with nemolizumab |
Late-breaking presentation Wednesday 25 September 4:30 – 4:45 pm CET Auditorium |
|
Prurigo nodularis |
M. Metz (presenting: FJ. Legat) |
Abstract #6224 Laboratory safety of nemolizumab in prurigo nodularis: Results from two phase 3 trials and one open-label extension study |
E-poser & oral presentation Thursday September 26 4:30 – 4:40 pm CET Open Stage |
|
Atopic dermatitis |
R. Sidbury |
Abstract #P0694 Efficacy and Safety of Nemolizumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Sub analysis from Two Phase 3 Randomized Clinical Trials (ARCADIA 1 and ARCADIA 2) after 16 weeks |
E-Posters E-Posters will be available for viewing in the e-Poster area, in the Wignacourt, level 6 of the Hilton Hotel - Conference Centre |
|
Atopic dermatitis / Prurigo nodularis |
N. Wagner |
Abstract #P1025 Absence of clinically impactful immunogenicity of nemolizumab in long-term treatment of patients with atopic dermatitis and prurigo nodularis |
|
|
Prurigo nodularis |
N. Wagner |
Abstract #P1026 Exposure response to support dose selection of nemolizumab in patients with prurigo nodularis |
|
|
Prurigo nodularis |
S. Ständer |
Abstract #P1040 Nemolizumab elicits an early and rapid itch response in prurigo nodularis within 2 days: A post hoc analysis of OLYMPIA 1 & 2 data |
|
|
Atopic dermatitis |
P. Lio |
Abstract #P0522 Incidence of comorbidities in a cohort of patients during the first year following initiation of systemic treatment for atopic dermatitis: a retrospective matched-control analysis of a US claims database |
|
|
Acne & sensitive skin |
|||
|
Acne |
J. Tan |
Abstract #P0028 Phase 4 Analyses: Trifarotene Reduces Atrophic Acne Scars Across All Skin Types With Greater Effect in Subjects with Higher Baseline Acne and Acne Scarring Severity |
Short oral presentation Thursday September 26 3:15 – 3:25pm CET Open Stage |
|
Acne |
A. Alexis |
Abstract #P0196 Unlocking the patient perspective: Exploring acne-induced post-inflammatory hyperpigmentation in the Phase 4 LEAP study |
E-Posters E-Posters will be available for viewing in the e-Poster area, in the Wignacourt, level 6 of the Hilton Hotel - Conference Centre |
|
Acne |
J. Tan |
Abstract #P0028 Phase 4 Analyses: Trifarotene Reduces Atrophic Acne Scars Across All Skin Types With Greater Effect in Subjects with Higher Baseline Acne and Acne Scarring Severity |
|
|
Acne |
JQ. Del Rosso |
Abstract #P0152 Efficacy, Tolerability, And Acceptability of A 2.6% Benzoyl Peroxide Acne Cleanser Specifically Designed for Sensitive Skin |
|
|
Acne |
M. Clément |
Abstract #P0140 Dermal patch: acne-prone skin management in modern dermatology |
|
|
Acne |
I. Berlin |
Abstract #P0139 Global perspective of acne and sensitive skin association in a multiethnic survey |
|
|
Acne |
B. Stephan |
Abstract #P0153 Epidemiology and health care of juvenile and late-onset acne – claims data analysis
|
|
|
Skin sensitivity |
M. Morse |
Abstract #P1165 Efficacy and safety of topical formulations on sensitive skin across 4 main ethnicities: A meta-analysis of clinical trials |
|
|
Sensitive skin |
E. McCormick
|
Abstract #P2658 Sensitive Skin: A Survey of Dermatology Resident Physicians’ Perspectives and Educational Exposures |
|
|
Sensitive skin |
C. Whiting |
Abstract #P2657 Primary Hyperhidrosis and Sensitive Skin Syndrome: A National Pilot Survey |
|
|
Sensitive skin
|
C. Ye
|
Abstract #P1848 A comparison between Lactic Acid Sting test and Sensitive Scale-10 in the diagnosis of Sensitive Skin |
|
|
Dermatological Skincare |
|||
|
Atopic dermatitis |
TQ. Nguyen |
Abstract #P0647 Comparison of Two OTC Itch Relief Products After Single Application |
E-Posters E-Posters will be available for viewing in the e-Poster area, in the Wignacourt, level 6 of the Hilton Hotel - Conference Centre |
|
Atopic dermatitis |
P. Lio |
Abstract #P0659 The Effect of a Soothing Moisturizer on Ceramide Levels in Patients with Eczema-Prone Skin |
|
|
Atopic dermatitis |
TQ. Nguyen |
Abstract #P0646 Comparison of a Soothing Moisturizer Versus Itch Relief Moisturizing Lotion on Hydration and TEWL in Patients with Eczema-Prone Skin |
|
|
Atopic dermatitis |
S. Anjuwon |
Abstract #P0633 A novel 2-step regimen improves severity, itch, and quality of life in an atopic dermatitis prone skin in a multi-ethnic population: a randomized clinical study |
|
|
Atopic dermatitis |
K. Hawley |
Abstract #P0660 A Novel 3-Step OTC Regimen Improves Eczema-Prone Skin Severity, Itch, and Life Quality: Randomized Study |
|
|
Psoriasis |
FG. Hougeir |
Abstract #P3317 Efficacy and Tolerability of a Sensitive Skin Cleansing and Moisturizing Regimen in Patients with Plaque Psoriasis Undergoing Prescription Treatment |
|
|
Skin hydration |
TQ. Nguyen |
Abstract #P1169 Heatmap Evaluation of Facial Hydration |
|
|
Skin hydration |
M. Afriat |
Abstract #P1166 A skincare regimen specifically designed for sensitive skin improves skin quality and hydration |
|
|
Wound healing |
AS. Farberg |
Abstract #P3676 Safety and Efficacy of a Healing Ointment as a Post-Surgical Wound Care |
|
|
Babies/Diaper rash |
TQ. Nguyen |
Abstract #P2872 Subject Perception of an OTC Healing Ointment to Prevent/Heal Diaper Rash in Infants |
|
|
Injectable aesthetics |
C. Blanché |
Abstract #P1167 Improved outcomes in injectable aesthetic procedures when combined with a customized skincare regimen |
All authors are paid consultants or employees of Galderma.
*Nemolizumab is an investigational drug in atopic dermatitis. Galderma received approval for its use in adults with prurigo nodularis in the U.S. (under the brand name Nemluvio®) in August 2024.